<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917393</url>
  </required_header>
  <id_info>
    <org_study_id>2040</org_study_id>
    <nct_id>NCT04917393</nct_id>
  </id_info>
  <brief_title>Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive</brief_title>
  <acronym>MODUS</acronym>
  <official_title>Multi-Organ Denervation to RedUce Sympathetic Drive, Multi-Center, Prospective Feasibility Study - The MODUS ON MED Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metavention</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metavention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety of multi-organ denervation using the&#xD;
      Integrated Radio Frequency (iRF) Denervation System. and to understand any potential&#xD;
      improvement in hypertension and glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, multi-center, non-randomized trial to evaluate the&#xD;
      initial safety and performance of multi-organ denervation for the treatment of hypertension&#xD;
      and type 2 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a prospective, single-arm, multi-center, non-randomized feasibility study</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of SADEs</measure>
    <time_frame>Index Procedure through 30 days.</time_frame>
    <description>The primary safety endpoint is the incidence rate of serious adverse device effects (SADEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in automated unobserved average office blood pressure</measure>
    <time_frame>90, 180 and 365 days</time_frame>
    <description>Change from baseline in systolic/diastolic blood pressure as indicated by average automated unobserved office blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic/Diastolic Blood Pressure - Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>90, 180 and 365 days</time_frame>
    <description>Change from baseline in systolic/diastolic blood pressure as indicated by ambulatory blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemic control - HbA1c</measure>
    <time_frame>90 days, 180 days and 365 days</time_frame>
    <description>Change from baseline in HbA1c percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemic control - fasting glucose</measure>
    <time_frame>90 days, 180 days and 365 days</time_frame>
    <description>Change from baseline in fasting plasma glucose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Multi-organ denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iRF System Multi-organ Denervation</intervention_name>
    <description>The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery</description>
    <arm_group_label>Multi-organ denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 80 years old&#xD;
&#xD;
          2. Office systolic blood pressure (SBP) ≥ 135 mmHg or on a stable dose of&#xD;
             antihypertensive medication(s) for at least 30 days&#xD;
&#xD;
          3. Documented daytime systolic ambulatory blood pressure (ABP) ≥ 135 and &lt; 175 mmHg&#xD;
&#xD;
          4. HbA1c ≥8.0% - ≤11.0% on a stable dose of antidiabetic medication(s) for at least 90&#xD;
             days&#xD;
&#xD;
          5. Waist circumference ≥ 102 cm (male) and ≥ 88 cm (female)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          6. Renal artery (RA) anatomy on either side OR common hepatic artery (CHA) anatomy,&#xD;
             ineligible for treatment including the following:&#xD;
&#xD;
               1. CHA OR RA artery diameter &lt; 4.0 mm or &gt; 7.0 mm&#xD;
&#xD;
               2. CHA OR RA artery length &lt; 20.0 mm&#xD;
&#xD;
               3. Only one functioning kidney&#xD;
&#xD;
               4. Presence of abnormal kidney tumors&#xD;
&#xD;
               5. CHA or RA with aneurysm&#xD;
&#xD;
               6. Pre-existing stent or history of angioplasty in target arteries&#xD;
&#xD;
               7. Fibromuscular dysplasia of the CHA or renal arteries&#xD;
&#xD;
               8. Presence of CHA OR RA diameter stenosis &gt;30%&#xD;
&#xD;
               9. Individual lacks appropriate arterial anatomy for treatment or for maneuvering of&#xD;
                  the device from the femoral artery to the target location(s)&#xD;
&#xD;
          7. Prior renal denervation procedure&#xD;
&#xD;
          8. Type 1 diabetes mellitus&#xD;
&#xD;
          9. Use of insulin within 90 days prior to Index Procedure&#xD;
&#xD;
         10. eGFR &lt; 45 mL/min per 1.73 m2&#xD;
&#xD;
         11. One or more documented severe hypertensive crisis (persistent or elevated hypertension&#xD;
             &gt; 180 mmHg accompanied by clinical symptoms) in the 90 days prior to Index Procedure&#xD;
&#xD;
         12. One or more documented hyperglycemia episodes (requiring hospitalization) in the 90&#xD;
             days prior to Index Procedure&#xD;
&#xD;
         13. One or more Severe hypoglycemic events (severe cognitive impairment requiring external&#xD;
             assistance for recovery) in the 90 days prior to Index Procedure&#xD;
&#xD;
         14. Evidence of active infection within 7 days prior to Index Procedure&#xD;
&#xD;
         15. Documented history of chronic active inflammatory bowel disorders such as Crohn's&#xD;
             disease or ulcerative colitis&#xD;
&#xD;
         16. Any history of cerebrovascular event (e.g., stroke, transient ischemic event, and&#xD;
             cerebrovascular accident) within 6 months prior to Index Procedure&#xD;
&#xD;
         17. Myocardial infarction within 6 months of Index Procedure&#xD;
&#xD;
         18. Heart failure (New York Heart Association [NYHA] Class III-IV) at time of consent.&#xD;
&#xD;
         19. Documented confirmed episode(s) of stable or unstable angina within 6 months prior to&#xD;
             Index Procedure&#xD;
&#xD;
         20. Documented history of persistent or permanent atrial tachyarrhythmia&#xD;
&#xD;
         21. Chronic oxygen support or mechanical ventilation other than nocturnal respiratory&#xD;
             support for sleep apnea&#xD;
&#xD;
         22. Night shift workers&#xD;
&#xD;
         23. Chronic regular use (e.g., daily use) of NSAIDs for 6 months or greater. Aspirin&#xD;
             therapy is allowed.&#xD;
&#xD;
         24. Active implantable medical device (e.g., ICD or CRT-D, neuromodulator/spinal&#xD;
             stimulator, baroreflex stimulator)&#xD;
&#xD;
         25. Known Primary pulmonary hypertension (HTN) (&gt; 60 mmHg pulmonary artery or right&#xD;
             ventricular systolic pressure)&#xD;
&#xD;
         26. Individual has known pheochromocytoma, Cushing syndrome, primary hyperaldosteronism,&#xD;
             coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or&#xD;
             primary hyperparathyroidism. (Note: Treated hyperthyroidism and treated hypothyroidism&#xD;
             are permissible.)&#xD;
&#xD;
         27. A history of bariatric surgery, baroreflex activation therapy, or liver transplant, or&#xD;
             these procedures are planned in the 365 days following Index Procedure&#xD;
&#xD;
         28. Previous hepatobiliary surgery/intervention that in the opinion of the investigator&#xD;
             could preclude the ability to perform denervation of the CHA&#xD;
&#xD;
         29. History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy&#xD;
             (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of&#xD;
             gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)&#xD;
&#xD;
         30. ALT or AST greater than 200 U/L&#xD;
&#xD;
         31. History or evidence of active / suspected chronic liver or biliary disease including&#xD;
             Hepatitis B, Hepatitis C, autoimmune hepatitis, primary biliary cholangitis (PBC),&#xD;
             primary sclerosing cholangitis, Wilson's disease, alpha-1-antitrypsin deficiency,&#xD;
             hemochromatosis, drug-induced liver disease, bile duct dilation and obstruction,&#xD;
             symptomatic gallstones, liver cancer or liver cirrhosis. Note: subjects with past&#xD;
             symptomatic gallstones and a cholecystectomy are not excluded.&#xD;
&#xD;
         32. Current or chronic pancreatitis&#xD;
&#xD;
         33. Documented contraindication or allergy to contrast medium not amenable to treatment&#xD;
&#xD;
         34. Limited life expectancy of &lt; 1 year at the discretion of the investigator&#xD;
&#xD;
         35. Any known, unresolved history of drug use or alcohol dependency, lacks the ability to&#xD;
             comprehend or follow instructions, or for any reason in the opinion of the&#xD;
             investigator, would be unlikely or unable to comply with study protocol requirements&#xD;
             or whose participation may result in data analysis confounders&#xD;
&#xD;
         36. Pregnant, nursing, or planning to become pregnant (documented negative pregnancy test&#xD;
             result required documented within a maximum of 7 days before Index Procedure for all&#xD;
             women of childbearing potential)&#xD;
&#xD;
         37. Concurrent enrollment in any other investigational drug or device trial (participation&#xD;
             in noninterventional registries is acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Ahlstrom</last_name>
    <phone>1-612-814-8208</phone>
    <email>aahlstrom@metavention.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Israeli-Georgian Medical Research Clinic Helsicore</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <keyword>Hepatic Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

